Globus Medical, Inc.

Equities

GMED

US3795772082

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-22 pm EDT 5-day change 1st Jan Change
51.25 USD +1.79% Intraday chart for Globus Medical, Inc. -1.10% -3.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
BTIG Upgrades Globus Medical to Buy From Neutral, Price Target is $60 MT
Globus Medical Insider Sold Shares Worth $405,730, According to a Recent SEC Filing MT
Atkore Insider Sold Shares Worth $2,195,228, According to a Recent SEC Filing MT
Truist Securities Adjusts Price Target on Globus Medical to $60 From $58, Keeps Hold Rating MT
Stifel Adjusts Globus Medical's Price Target to $64 From $61, Keeps Buy Rating MT
Tranche Update on Globus Medical, Inc.'s Equity Buyback Plan announced on March 12, 2020. CI
Globus Medical Q4 Non-GAAP Earnings, Revenue Increase; Sets 2024 Guidance MT
Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024 CI
Transcript : Globus Medical, Inc., Q4 2023 Earnings Call, Feb 20, 2024
Earnings Flash (GMED) GLOBUS MEDICAL Reports Q4 EPS $0.60, vs. Street Est of $0.61 MT
Earnings Flash (GMED) GLOBUS MEDICAL Reports Q4 Revenue $616.5M, vs. Street Est of $608.2M MT
Globus Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Globus Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Globus Medical Appoints CFO Keith Pfeil to Additional Role of Chief Operating Officer MT
Globus Medical Promotes Keith Pfeil to Chief Operating Officer CI
Global markets live: UBS, Netflix, Pfizer, Citigroup, Alphabet... Our Logo
Investors keep their cool despite inflation data Our Logo
Globus Medical Reports Preliminary Q4, 2023 Sales, Issues 2024 Profit, Revenue Guidance MT
Globus Medical, Inc. Provides Sales Results for the Fourth Quarter and Full Year Ending December 31, 2023; Provides Earnings Guidance for the Full Year Fiscal 2024 CI
Truist Adjusts Price Target on Globus Medical to $58 From $53, Maintains Hold Rating MT
Canaccord Genuity Adjusts Globus Medical's Price Target to $71 From $67, Keeps Buy Rating MT
RBC Cuts Price Target on Globus Medical to $70 From $77, Keeps Outperform Rating MT
Morgan Stanley Cuts Price Target on Globus Medical to $53 From $60, Maintains Equalweight Rating MT
Truist Securities Adjusts Price Target on Globus Medical to $53 From $58, Maintains Hold Rating MT
Chart Globus Medical, Inc.
More charts
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
51.25 USD
Average target price
64.89 USD
Spread / Average Target
+26.61%
Consensus
  1. Stock Market
  2. Equities
  3. GMED Stock
  4. News Globus Medical, Inc.
  5. Globus Medical : SVB Leerink Adjusts Globus Medical PT to $81 From $74, Maintains Outperform Rating